Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study

Morris Kletzel, Howard M. Katzenstein, Paul Haut, Alice L. Yu, Elaine Morgan, Marleta Reynolds, Grant Geissler, Maryanne H. Marymount, Dachao Liu, John A. Kalapurakal, Richard M. Shore, Diana M E Bardo, Jennifer Schmoldt, Alfred W. Rademaker, Susan L. Cohn

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II Protocol. After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of high-dose cyclophosphamide and granulocyte colony-stimulating factor. Patients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the primary site. Results: Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Sufficient numbers of peripheral-blood stem cells were collected in all but one patient. Seventeen patients were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycles, and three patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. With a median follow-up of 38 months, the 3-year event-free survival and survival rates are 57% ± 11% and 79% ± 10%, respectively. Conclusion: The results of this pilot study demonstrate that it is feasible to intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and suggest that this treatment strategy may lead to improved survival for patients with high-risk neuroblastoma.

Original languageEnglish (US)
Pages (from-to)2284-2292
Number of pages9
JournalJournal of Clinical Oncology
Volume20
Issue number9
DOIs
StatePublished - May 1 2002
Externally publishedYes

Fingerprint

Neuroblastoma
Stem Cells
Therapeutics
Disease-Free Survival
Poisons
Granulocyte Colony-Stimulating Factor
Treatment Failure
Cyclophosphamide
Peripheral Blood Stem Cells
Survival Rate
Radiation
Transplants
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue : Results of the Chicago Pilot II study. / Kletzel, Morris; Katzenstein, Howard M.; Haut, Paul; Yu, Alice L.; Morgan, Elaine; Reynolds, Marleta; Geissler, Grant; Marymount, Maryanne H.; Liu, Dachao; Kalapurakal, John A.; Shore, Richard M.; Bardo, Diana M E; Schmoldt, Jennifer; Rademaker, Alfred W.; Cohn, Susan L.

In: Journal of Clinical Oncology, Vol. 20, No. 9, 01.05.2002, p. 2284-2292.

Research output: Contribution to journalArticle

Kletzel, M, Katzenstein, HM, Haut, P, Yu, AL, Morgan, E, Reynolds, M, Geissler, G, Marymount, MH, Liu, D, Kalapurakal, JA, Shore, RM, Bardo, DME, Schmoldt, J, Rademaker, AW & Cohn, SL 2002, 'Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study', Journal of Clinical Oncology, vol. 20, no. 9, pp. 2284-2292. https://doi.org/10.1200/JCO.2002.06.060
Kletzel, Morris ; Katzenstein, Howard M. ; Haut, Paul ; Yu, Alice L. ; Morgan, Elaine ; Reynolds, Marleta ; Geissler, Grant ; Marymount, Maryanne H. ; Liu, Dachao ; Kalapurakal, John A. ; Shore, Richard M. ; Bardo, Diana M E ; Schmoldt, Jennifer ; Rademaker, Alfred W. ; Cohn, Susan L. / Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue : Results of the Chicago Pilot II study. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 9. pp. 2284-2292.
@article{7362f23d82994219bee877535342a267,
title = "Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II study",
abstract = "Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II Protocol. After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of high-dose cyclophosphamide and granulocyte colony-stimulating factor. Patients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the primary site. Results: Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Sufficient numbers of peripheral-blood stem cells were collected in all but one patient. Seventeen patients were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycles, and three patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. With a median follow-up of 38 months, the 3-year event-free survival and survival rates are 57{\%} ± 11{\%} and 79{\%} ± 10{\%}, respectively. Conclusion: The results of this pilot study demonstrate that it is feasible to intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and suggest that this treatment strategy may lead to improved survival for patients with high-risk neuroblastoma.",
author = "Morris Kletzel and Katzenstein, {Howard M.} and Paul Haut and Yu, {Alice L.} and Elaine Morgan and Marleta Reynolds and Grant Geissler and Marymount, {Maryanne H.} and Dachao Liu and Kalapurakal, {John A.} and Shore, {Richard M.} and Bardo, {Diana M E} and Jennifer Schmoldt and Rademaker, {Alfred W.} and Cohn, {Susan L.}",
year = "2002",
month = "5",
day = "1",
doi = "10.1200/JCO.2002.06.060",
language = "English (US)",
volume = "20",
pages = "2284--2292",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue

T2 - Results of the Chicago Pilot II study

AU - Kletzel, Morris

AU - Katzenstein, Howard M.

AU - Haut, Paul

AU - Yu, Alice L.

AU - Morgan, Elaine

AU - Reynolds, Marleta

AU - Geissler, Grant

AU - Marymount, Maryanne H.

AU - Liu, Dachao

AU - Kalapurakal, John A.

AU - Shore, Richard M.

AU - Bardo, Diana M E

AU - Schmoldt, Jennifer

AU - Rademaker, Alfred W.

AU - Cohn, Susan L.

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II Protocol. After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of high-dose cyclophosphamide and granulocyte colony-stimulating factor. Patients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the primary site. Results: Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Sufficient numbers of peripheral-blood stem cells were collected in all but one patient. Seventeen patients were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycles, and three patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. With a median follow-up of 38 months, the 3-year event-free survival and survival rates are 57% ± 11% and 79% ± 10%, respectively. Conclusion: The results of this pilot study demonstrate that it is feasible to intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and suggest that this treatment strategy may lead to improved survival for patients with high-risk neuroblastoma.

AB - Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II Protocol. After induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of high-dose cyclophosphamide and granulocyte colony-stimulating factor. Patients then underwent triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the primary site. Results: Twenty-two of the 26 patients successfully completed induction therapy and were eligible for the triple-tandem consolidation high-dose therapy. Sufficient numbers of peripheral-blood stem cells were collected in all but one patient. Seventeen patients were able to complete all three cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycles, and three patients completed one cycle. There was one toxic death, and one patient died from complications of treatment for graft failure. With a median follow-up of 38 months, the 3-year event-free survival and survival rates are 57% ± 11% and 79% ± 10%, respectively. Conclusion: The results of this pilot study demonstrate that it is feasible to intensify consolidation with triple-tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and suggest that this treatment strategy may lead to improved survival for patients with high-risk neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=0036569839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036569839&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.06.060

DO - 10.1200/JCO.2002.06.060

M3 - Article

C2 - 11980999

AN - SCOPUS:0036569839

VL - 20

SP - 2284

EP - 2292

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -